6 results on '"Sanaz Baghban Rahimi"'
Search Results
2. What family doctors know about congenital CMV: a regional survey in Iran
- Author
-
Ahmad Hosseinzadeh Adli, Chiman Karami, Sanaz Baghban Rahimi, Azam Mirarab, and Alijan Tabarraei
- Subjects
Congenital cytomegalovirus ,cCMV ,Awareness ,Doctors ,Iran ,Pediatrics ,RJ1-570 - Abstract
Abstract Background Since there is no effective treatment or vaccine against the congenital cytomegalovirus (cCMV) infection, knowledge and awareness of medical doctor’s (MDs) especially family doctors are essential for preventive strategies and it also seems to be usually ignored by healthcare providers. Aim of this study was to investigate awareness of MDs about cCMV infection in Iran. Methods A single page questionnaire was randomly distributed among 450 MDs including general practitioners, pediatricians, gynecologists, internal and other medical specialists concerning of their knowledge in clinical presentation, diagnosis, prevention, prognosis, epidemiology, transmission, and management of cCMV infection. All statistical analyses were performed using SPSS version 16. Results More than half of questionnaire recipients refused to take part in any of the questionnaire items. The most of the respondents were agreed for newborn CMV screening tests and mandatory CMV test for women trying to get pregnant, which, are not routinely tested. The knowledge of general practitioners about cCMV was less than usual. The field of expertise had a profound effect in this survey, but age and gender did not. Conclusions Our results indicated that the knowledge of cCMV infection, especially among family doctors contains several gaps. Urgent action is required to improve family doctor’s knowledge of CMV infection. Surveys to evaluate CMV awareness among MDs, healthcare professionals and women of childbearing age are proposed.
- Published
- 2018
- Full Text
- View/download PDF
3. Enhanced Th1 and Th2 immune response induction by Human Papilloma virus Type 16 E7 DNA vaccine in a tumoric murine model
- Author
-
Alireza Mohebbi, Sanaz Baghban Rahimi, Alijan Tabarraei, Mohsen Saeedi, Mirsaeed Ebrahimzadeh, Leila Alizadeh, and Amir Ghaemi
- Subjects
E7 DNA vaccine ,Human papillomavirus ,cytokine ,cellular immunity ,cervical cancer ,Medicine ,Biology (General) ,QH301-705.5 - Abstract
Background and Objectives: Human papilloma virus (HPV) is known as the etiologic agent of cervical cancer and second common cancer among women. HPV viruses with the elevated risk of infection have more potentiality to cause cancer. The carcinogenesis in these viruses is accomplished by oncoproteins such as E7. Employing DNA vaccines which code specific antigens such as E7 is a novel therapeutic approach against such cancers. Methods: In the present study, plasmid coding HPV16 E7 was administered intracutaneously to C57BL/6 tumoric mice models for investigation of its immunostimulating potential. PcDNA3.1+ vector was used as control vector. After immunization, spleen of animals were removed. Then, release of lactate dehydrogenase (LDH) was evaluated to address the cytotoxic activity (CTL) induced by cellular immunity in spleenocytes. Interferon-γ (IFN-γ) and interleukin-4 (IL-4) cytokines were also analyzed as profiles of Th1 and Th2, respectively. Anti-inflammatory cytokine interleukin-10 (IL-10) levels were also investigated in tumor microenvironments. Results: Our results showed that CTL activity was higher among samples receiving HPV16 E7 coding vector in comparison to the group receiving pcDNA3.1+ control vector (P < 0.05). Levels of IFN-γ and IL-4 were also higher in the group receiving HPV16 E7 plasmid in comparison to the control group (P < 0.05). Similarly, IL-10 levels were significantly lower in tumor carrying mice groups receiving HPV16 DNA vaccine compare to PBS and pcDNA3.1 receiving control groups. Conclusion: HPV16 E7 expressing DNA vaccine could increase the release of LDH due to immune system CTL activity. Elevation in IFN-γ and IL-4 levels as well as IL-10 reduction indicates an increase in both Th1 and Th2 profiles resulted by using potent DNA vaccine coding HPV16 E7 in tumor animal model.
- Published
- 2017
4. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells
- Author
-
Gelareh Vakilzadeh, Peyvand Biglari, Seyed Reza Mohebi, Sadegh Shirian, Amir Ghaemi, Ali Gorji, Alireza Mohebbi, Sanaz Baghban Rahimi, and Soodeh Razeghi Jahromi
- Subjects
Vascular Endothelial Growth Factor A ,0301 basic medicine ,Papillomavirus E7 Proteins ,medicine.medical_treatment ,Lymphocyte proliferation ,Biology ,Lymphocyte Activation ,Cancer Vaccines ,DNA vaccination ,Interferon-gamma ,Mice ,03 medical and health sciences ,Adjuvants, Immunologic ,Cell Line, Tumor ,Virology ,Vaccines, DNA ,medicine ,Splenocyte ,Animals ,Cytotoxic T cell ,Papillomavirus Vaccines ,Cell Proliferation ,Melatonin ,Human papillomavirus 16 ,Tumor microenvironment ,Tumor Necrosis Factor-alpha ,Papillomavirus Infections ,Vaccination ,Epithelial Cells ,General Medicine ,Survival Analysis ,Tumor Burden ,Mice, Inbred C57BL ,030104 developmental biology ,Gene Expression Regulation ,Female ,Interleukin-4 ,Cancer vaccine ,Adjuvant ,Plasmids ,T-Lymphocytes, Cytotoxic - Abstract
To be effective, therapeutic cancer vaccines should stimulate both an effective cell-mediated and a robust cytotoxic CD8+ T-cell response against human papillomavirus (HPV)-infected cells to treat the pre-existing tumors and prevent potential future tumors. In this study, the therapeutic experiments were designed in order to evaluate antitumor effect against the syngeneic TC-1 tumor model. The anti-tumor efficacy of a HPV-16 E7 DNA vaccine adjuvanted with melatonin (MLT) was evaluated in a C57BL/6 mouse tumor model by measuring tumor growth post vaccination and the survival rate of tumor-bearing mice, analyzing the specific lymphocyte proliferation responses in control and vaccinated mice by MTT assay. The E7-specific cytotoxic T cells (CTL) were analyzed by lymphocyte proliferation and lactate dehydrogenates (LDH) release assays. IFN-γ, IL-4 and TNF-α secretion in splenocyte cultures as well as vascular endothelial growth factor (VEGF) and IL-10 in the tumor microenvironment were assayed by ELISA. Our results demonstrated that subcutaneous administration of C57BL/6 mice with a DNA vaccine adjuvanted with MLT dose-dependently and significantly induced strong HPV16 E7-specific CD8+ cytotoxicity and IFN-γ and TNF-α responses capable of reducing HPV-16 E7-expressing tumor volume. A significantly higher level of E7-specific T-cell proliferation was also found in the adjuvanted vaccine group. Furthermore, tumor growth was significantly inhibited when the DNA vaccine was combined with MLT and the survival time of TC-1 tumor bearing mice was also significantly prolonged. In vivo studies further demonstrated that MLT decreased the accumulation of IL-10 and VEGF in the tumor microenvironment of vaccinated mice. These data indicate that melatonin as an adjuvant augmented the cancer vaccine efficiency against HPV-associated tumors in a dose dependent manner.
- Published
- 2017
5. Non-replicating Newcastle Disease Virus as an adjuvant for DNA vaccine enhances antitumor efficacy through the induction of TRAIL and granzyme B expression
- Author
-
Sadegh Shirian, Mohsen Saeidi, Seyed Reza Mohebbi, Alireza Mohebbi, Amir Ghaemi, Alijan Tabarraei, Ali Gorji, Mir Saeed Ebrahimzadeh, and Sanaz Baghban Rahimi
- Subjects
Cancer Research ,Cellular immunity ,Lung Neoplasms ,animal diseases ,viruses ,medicine.medical_treatment ,Biology ,Vaccines, Attenuated ,Cancer Vaccines ,Granzymes ,DNA vaccination ,TNF-Related Apoptosis-Inducing Ligand ,03 medical and health sciences ,Adjuvants, Immunologic ,Immunity ,Virology ,Cell Line, Tumor ,medicine ,Splenocyte ,Vaccines, DNA ,Animals ,030304 developmental biology ,Cell Proliferation ,0303 health sciences ,Tumor microenvironment ,Human papillomavirus 16 ,030306 microbiology ,Viral Vaccines ,Oncogene Proteins, Viral ,biochemical phenomena, metabolism, and nutrition ,Granzyme B ,Mice, Inbred C57BL ,Disease Models, Animal ,Infectious Diseases ,Treatment Outcome ,Tumor progression ,Cancer research ,Cytokines ,Female ,Adjuvant ,T-Lymphocytes, Cytotoxic - Abstract
The potential of non-replicating Newcastle Disease Virus (NDV) as an adjuvant for DNA vaccination remains to be elucidated. To assess the therapeutic effects of DNA vaccine (HPV-16 E7 gene) adjuvanted with NDV, female C57/BL6 mice were inoculated with murine TC-1 cells of human papillomavirus (HPV)-related carcinoma, expressing human papillomavirus 16 (HPV-16) E6/E7 antigens, and immunized with DNA vaccine alone or pretreated with NDV. One week after third immunization, Cytotoxic T lymphocytes (CTLs), splenocyte proliferation, cytokine balance (IFN-γ, IL-4 and IL-12 secretions) and intratumoral expression of cytotoxicity related proteins in tumor lysates were investigated. The results showed that treatment with non-replicating NDV prior to DNA vaccine induced tumor-specific cytolytic and splenocyte proliferation responses. The levels of cytokines IL-12, IL-4 and IFN-γ after treating with combined E7-DNA -non-replicating NDV (NDV-DNA Vaccine) were significantly higher than those of control groups. The intratumoral granzyme B and Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL)-mediated apoptosis was also significantly increased. Tumor therapeutic experiments showed that the NDV pretreatment could reduce the tumor progression of established E7-expressing TC-tumors. Taken together these data suggest that the significant antitumor responses evidenced during treatment with non-replicating NDV prior to DNA vaccine are due, in part, to strong E7-induced cellular immunity and enhanced expression of cytotoxicity related proteins in the tumor microenvironment. These observations indicated the potential of non-replicating NDV as an adjuvant for enhancing therapeutic DNA vaccines -induced immunity and antitumor responses.
- Published
- 2018
6. What family doctors know about congenital CMV: a regional survey in Iran
- Author
-
Azam Mirarab, Sanaz Baghban Rahimi, Chiman Karami, Alijan Tabarraei, and Ahmad Hosseinzadeh Adli
- Subjects
Adult ,Male ,medicine.medical_specialty ,Cross-sectional study ,Cytomegalovirus ,Iran ,03 medical and health sciences ,Cytomegalovirus Vaccines ,0302 clinical medicine ,030225 pediatrics ,Surveys and Questionnaires ,Epidemiology ,medicine ,Effective treatment ,Humans ,030212 general & internal medicine ,business.industry ,Transmission (medicine) ,Congenital cmv ,Incidence (epidemiology) ,Research ,Incidence ,Doctors ,lcsh:RJ1-570 ,Physicians, Family ,lcsh:Pediatrics ,Awareness ,Test (assessment) ,Congenital cytomegalovirus ,cCMV ,Cross-Sectional Studies ,Family medicine ,Cytomegalovirus Infections ,Family doctors ,Female ,Clinical Competence ,business - Abstract
Background Since there is no effective treatment or vaccine against the congenital cytomegalovirus (cCMV) infection, knowledge and awareness of medical doctor’s (MDs) especially family doctors are essential for preventive strategies and it also seems to be usually ignored by healthcare providers. Aim of this study was to investigate awareness of MDs about cCMV infection in Iran. Methods A single page questionnaire was randomly distributed among 450 MDs including general practitioners, pediatricians, gynecologists, internal and other medical specialists concerning of their knowledge in clinical presentation, diagnosis, prevention, prognosis, epidemiology, transmission, and management of cCMV infection. All statistical analyses were performed using SPSS version 16. Results More than half of questionnaire recipients refused to take part in any of the questionnaire items. The most of the respondents were agreed for newborn CMV screening tests and mandatory CMV test for women trying to get pregnant, which, are not routinely tested. The knowledge of general practitioners about cCMV was less than usual. The field of expertise had a profound effect in this survey, but age and gender did not. Conclusions Our results indicated that the knowledge of cCMV infection, especially among family doctors contains several gaps. Urgent action is required to improve family doctor’s knowledge of CMV infection. Surveys to evaluate CMV awareness among MDs, healthcare professionals and women of childbearing age are proposed. Electronic supplementary material The online version of this article (10.1186/s13052-018-0470-4) contains supplementary material, which is available to authorized users.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.